162 related articles for article (PubMed ID: 34557821)
1. The impact of the COVID-19 pandemic on organised cervical cancer screening: The first results of the Slovenian cervical screening programme and registry.
Ivanuš U; Jerman T; Gašper Oblak U; Meglič L; Florjančič M; Strojan Fležar M; Premru Sršen T; Smrkolj Š; Pakiž M; Primic Žakelj M; Kloboves Prevodnik V; Pogačnik A; Josipović I; Mate T; Gobec M
Lancet Reg Health Eur; 2021 Jun; 5():100101. PubMed ID: 34557821
[TBL] [Abstract][Full Text] [Related]
2. [Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors].
Ronco G; Biggeri A; Confortini M; Naldoni C; Segnan N; Sideri M; Zappa M; Zorzi M; Calvia M; Accetta G; Giordano L; Cogo C; Carozzi F; Gillio Tos A; Arbyn M; Mejier CJ; Snijders PJ; Cuzick J; Giorgi Rossi P
Epidemiol Prev; 2012; 36(3-4 Suppl 1):e1-72. PubMed ID: 22828243
[TBL] [Abstract][Full Text] [Related]
3. Three-year longitudinal data on the clinical performance of the Abbott RealTime High Risk HPV test in a cervical cancer screening setting.
Poljak M; Oštrbenk A; Seme K; Šterbenc A; Jančar N; Vrtačnik Bokal E
J Clin Virol; 2016 Mar; 76 Suppl 1():S29-S39. PubMed ID: 26643051
[TBL] [Abstract][Full Text] [Related]
4. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial.
Canfell K; Caruana M; Gebski V; Darlington-Brown J; Heley S; Brotherton J; Gertig D; Jennett CJ; Farnsworth A; Tan J; Wrede CD; Castle PE; Saville M
PLoS Med; 2017 Sep; 14(9):e1002388. PubMed ID: 28926579
[TBL] [Abstract][Full Text] [Related]
5. Randomised healthcare policy evaluation of organised primary human papillomavirus screening of women aged 56-60.
Lamin H; Eklund C; Elfström KM; Carlsten-Thor A; Hortlund M; Elfgren K; Törnberg S; Dillner J
BMJ Open; 2017 May; 7(5):e014788. PubMed ID: 28566363
[TBL] [Abstract][Full Text] [Related]
6. Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020-99: a modelling study.
Simms KT; Steinberg J; Caruana M; Smith MA; Lew JB; Soerjomataram I; Castle PE; Bray F; Canfell K
Lancet Oncol; 2019 Mar; 20(3):394-407. PubMed ID: 30795950
[TBL] [Abstract][Full Text] [Related]
7. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
8. Randomised trial of HPV self-sampling among non-attenders in the Slovenian cervical screening programme ZORA: comparing three different screening approaches.
Ivanus U; Jerman T; Fokter AR; Takac I; Prevodnik VK; Marcec M; Gajsek US; Pakiz M; Koren J; Celik SH; Kramberger KG; Klopcic U; Kavalar R; Zatler SS; Kuzmanov BG; Florjancic M; Nolde N; Novakovic S; Poljak M; Zakelj MP
Radiol Oncol; 2018 Sep; 52(4):399-412. PubMed ID: 30216191
[TBL] [Abstract][Full Text] [Related]
9. Cervical cancer screening: A Slovenian experience.
Primic-Zakelj M; Repse-Fokter A
Coll Antropol; 2007 Apr; 31 Suppl 2():23-6. PubMed ID: 17600934
[TBL] [Abstract][Full Text] [Related]
10. HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT.
Gilham C; Sargent A; Kitchener HC; Peto J
Health Technol Assess; 2019 Jun; 23(28):1-44. PubMed ID: 31219027
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial.
Ronco G; Giorgi-Rossi P; Carozzi F; Confortini M; Dalla Palma P; Del Mistro A; Ghiringhello B; Girlando S; Gillio-Tos A; De Marco L; Naldoni C; Pierotti P; Rizzolo R; Schincaglia P; Zorzi M; Zappa M; Segnan N; Cuzick J;
Lancet Oncol; 2010 Mar; 11(3):249-57. PubMed ID: 20089449
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic accuracy of cervical cancer screening strategies for high-grade cervical intraepithelial neoplasia (CIN2+/CIN3+) among women living with HIV: A systematic review and meta-analysis.
Kelly H; Jaafar I; Chung M; Michelow P; Greene S; Strickler H; Xie X; Schiffman M; Broutet N; Mayaud P; Dalal S; Arbyn M; de Sanjosé S
EClinicalMedicine; 2022 Nov; 53():101645. PubMed ID: 36187721
[TBL] [Abstract][Full Text] [Related]
13. Impact of variations in triage cytology interpretation on human papillomavirus-based cervical screening and implications for screening algorithms.
Ronco G; Zappa M; Franceschi S; Tunesi S; Caprioglio A; Confortini M; Del Mistro A; Carozzi F; Segnan N; Zorzi M; Giorgi-Rossi P;
Eur J Cancer; 2016 Nov; 68():148-155. PubMed ID: 27755998
[TBL] [Abstract][Full Text] [Related]
14. Long term results of follow-up after HPV self-sampling with devices Qvintip and HerSwab in women non-attending cervical screening programme.
Bokan T; Ivanus U; Jerman T; Takac I; Arko D
Radiol Oncol; 2021 Jan; 55(2):187-195. PubMed ID: 33764704
[TBL] [Abstract][Full Text] [Related]
15. [HPV-Hr detection by home self sampling in women not compliant with pap test for cervical cancer screening. Results of a pilot programme in Bouches-du-Rhône].
Piana L; Leandri FX; Le Retraite L; Heid P; Tamalet C; Sancho-Garnier H
Bull Cancer; 2011 Jul; 98(7):723-31. PubMed ID: 21700548
[TBL] [Abstract][Full Text] [Related]
16. Pan-Canadian survey on the impact of the COVID-19 pandemic on cervical cancer screening and management: cross-sectional survey of healthcare professionals.
El-Zein M; Ali R; Farah E; Botting-Provost S; Franco EL;
Elife; 2023 Jun; 12():. PubMed ID: 37377399
[TBL] [Abstract][Full Text] [Related]
17. [Health technology assessment report: Computer-assisted Pap test for cervical cancer screening].
Della Palma P; Moresco L; Giorgi Rossi P
Epidemiol Prev; 2012; 36(5 Suppl 3):e1-43. PubMed ID: 23139174
[TBL] [Abstract][Full Text] [Related]
18. Implementation of HPV-based cervical cancer screening in an organised regional screening programme: 3 years of experience.
Veijalainen O; Kares S; Kujala P; Vuento R; Osuala V; Tirkkonen M; Luukkaala T; Kholová I; Mäenpää J
Cytopathology; 2019 Mar; 30(2):150-156. PubMed ID: 30421573
[TBL] [Abstract][Full Text] [Related]
19. Introduction of primary screening using high-risk HPV DNA detection in the Dutch cervical cancer screening programme: a population-based cohort study.
Aitken CA; van Agt HME; Siebers AG; van Kemenade FJ; Niesters HGM; Melchers WJG; Vedder JEM; Schuurman R; van den Brule AJC; van der Linden HC; Hinrichs JWJ; Molijn A; Hoogduin KJ; van Hemel BM; de Kok IMCM
BMC Med; 2019 Dec; 17(1):228. PubMed ID: 31829241
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
